Next Article in Journal
Molecular Recognition of the HPLC Whelk-O1 Selector towards the Conformational Enantiomers of Nevirapine and Oxcarbazepine
Next Article in Special Issue
Pregnancy-Induced High Plasma Levels of Soluble Endoglin in Mice Lead to Preeclampsia Symptoms and Placental Abnormalities
Previous Article in Journal
Antiproliferative Effects of St. John’s Wort, Its Derivatives, and Other Hypericum Species in Hematologic Malignancies
Previous Article in Special Issue
Endoglin: An ‘Accessory’ Receptor Regulating Blood Cell Development and Inflammation

Endoglin Targeting: Lessons Learned and Questions That Remain

Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Department of Gastroenterology and Hepatology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
Author to whom correspondence should be addressed.
These authors contributed equally to the work.
Int. J. Mol. Sci. 2021, 22(1), 147;
Received: 9 December 2020 / Revised: 21 December 2020 / Accepted: 22 December 2020 / Published: 25 December 2020
(This article belongs to the Special Issue Endoglin in Health and Disease)
Approximately 30 years ago, endoglin was identified as a transforming growth factor (TGF)-β coreceptor with a crucial role in developmental biology and tumor angiogenesis. Its selectively high expression on tumor vessels and its correlation with poor survival in cancer patients led to the exploration of endoglin as a therapeutic target for cancer. The endoglin neutralizing antibody TRC105 (Carotuximab®, Tracon Pharmaceuticals (San Diego, CA, USA) was subsequently tested in a wide variety of preclinical cancer models before being tested in phase I-III clinical studies in cancer patients as both a monotherapy and in combination with other chemotherapeutic and anti-angiogenic therapies. The combined data of these studies have revealed new insights into the role of endoglin in angiogenesis and its expression and functional role on other cells in the tumor microenvironment. In this review, we will summarize the preclinical work, clinical trials and biomarker studies of TRC105 and explore what these studies have enabled us to learn and what questions remain unanswered. View Full-Text
Keywords: endoglin; TRC105; angiogenesis; clinical trials; biomarkers endoglin; TRC105; angiogenesis; clinical trials; biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Liu, Y.; Paauwe, M.; Nixon, A.B.; Hawinkels, L.J.A.C. Endoglin Targeting: Lessons Learned and Questions That Remain. Int. J. Mol. Sci. 2021, 22, 147.

AMA Style

Liu Y, Paauwe M, Nixon AB, Hawinkels LJAC. Endoglin Targeting: Lessons Learned and Questions That Remain. International Journal of Molecular Sciences. 2021; 22(1):147.

Chicago/Turabian Style

Liu, Yingmiao; Paauwe, Madelon; Nixon, Andrew B.; Hawinkels, Lukas J.A.C. 2021. "Endoglin Targeting: Lessons Learned and Questions That Remain" Int. J. Mol. Sci. 22, no. 1: 147.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop